Avastin as an Adjunct to Diode Laser Cyclophotoablation in the Treatment of Neovascular Glaucoma
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Sponsor
- Cairo University
- Enrollment
- 16
- Locations
- 1
- Primary Endpoint
- Disappearance of iris neovessels
Study Overview
Brief Summary
Assess the efficacy of Avastin as an adjunct to Diode Laser cyclophotocoagulation in the treatment of Neovascular Glaucoma.
Detailed Description
Design: Prospective, comparative interventional case series. Method: Patients were randomly assigned into Group A which were treated with Diode laser cyclophotocoagulation alone, whereas group B received intravitreal Avastin (One milligram = 0.04mL of 25 mg/mL) in conjunction with the Diode Laser. The preoperative data included etiology, mean age; follow up period, and a full ophthalmological examination with emphasis on mean IOP, iris neovascularization, pain and corneal edema.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 14 Years to 72 Years (Child, Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Neovascular absolute glaucoma
- •Painful blind eyes
Exclusion Criteria
- •Neovascular glaucoma with useful vision or potential for useful vision
Arms & Interventions
Avastin , diode laser cyclophotcoagulation
Intravitreal Avastin injection in conjunction with diode laser cyclophotocoagulation
Intervention: Diode laser cyclophotocoagulation enhanced by intravitreal injection of Avastin (Procedure)
Diode Laser cyclophotocoagulation
Diode laser cyclophotocoagulation to control intraocular pressure
Intervention: Diode laser cyclophotocoagulation enhanced by intravitreal injection of Avastin (Procedure)
Outcomes
Primary Outcomes
Disappearance of iris neovessels
Time Frame: 2 weeks
Secondary Outcomes
- Intra ocular pressure(4 weeks)